Reuters - U.S. lawmakers tussled on Thursday over how long makers of biotechnology drugs should have an exclusive license for the expensive medicines in a hearing called to discuss a Federal Trade Commission report on the issue.
Original post by Reuters and software by Elliott Back
Continue reading about U.S. lawmakers tussle over generic biologic drugs (Reuters)
Recent Comments